Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR
Anxiety Disorders
About this trial
This is an interventional treatment trial for Anxiety Disorders focused on measuring Generalized Anxiety Disorder, Chronic Mediation Treatment, Double-Blind, Placebo Controlled, Venlafaxine XR, Relapse
Eligibility Criteria
Inclusion Criteria: GAD diagnosis by structured interview Hamilton Anxiety Scale score of 18 or MORE Clinical Global Impressions Severity Scale score of at least 4 Hamilton Depression Scale score of 18 or less Hamilton Depression Scale suicide item score less than 2 Use of an effective form of contraception throughout the study Exclusion Criteria: Hypersensitivity to venlafaxine XR History of seizures Episode of major depressive disorder in the previous 6 months History of any psychotic illness, bipolar disorder, or dementia Substance abuse and dependence during the past 6 months Other anxiety disorders with the exception of social phobia as long as GAD is primary Regular use of anxiolytics or antidepressants within 7 days of study onset Use of fluoxetine or monoamine oxidase inhibitors within 28 days of study onset (low dose usage of benzodiazepines will not prevent participation) Use of other psychotropic medication besides benzodiazepines during the study
Sites / Locations
- University of Pennsylvania, 3535 Market Street, Suite 670
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Active Comparator
Active Comparator
Placebo Comparator
Active Comparator
Placebo Comparator
Placebo Comparator
Open-Label Group
Double-Blind Drug Group
Double-Blind Placebo Group
Double-Blind Drug-After-Drug Group
Double-Blind Placebo-After-Drug Group
Double-Blind Placebo-After-Placebo Group
6-month randomized phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d
6-month randomized, double-blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 6 - 12 of the study
6-month randomized, double blind phase of placebo occurring between months 6 - 12 of the study
6-month randomized, double blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 13 - 19 of the study
6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study